


PHARMACEUTICAL 2018

EnzymeBioSystems Rank 342 of 349





PHARMACEUTICAL 2018

EnzymeBioSystems Rank 342 of 349

The relative strengths and weaknesses of EnzymeBioSystems are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EnzymeBioSystems compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 542% points. The greatest weakness of EnzymeBioSystems is the variable Other Expenses, reducing the Economic Capital Ratio by 1,667% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,426%, being 1,149% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	44
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0.10
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	111
Other Liabilities	4.0
Other Net Income	15
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	44
Liabilities	4.1
Expenses	111
Stockholders Equity	40
Net Income	-96
Comprehensive Net Income	-96
Economic Capital Ratio	-1,426%